-
公开(公告)号：WO2004031231A3
公开(公告)日：2004-07-08
申请号：PCT/JP0312074
申请日：2003-09-22
Applicant: ONCOTHERAPY SCIENCE INC , JAPAN AS REPRESENTED BY THE PR , NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
CPC classification number: C07K14/47 , C12Q1/6886 , C12Q2600/136
Abstract: The present application provides novel human gene MICAL2-PV whose expression is markedly elevated in prostate cancers. Furthermore, it provides polypeptides encoded by the gene as well as polypeptides encoded by PCOTH which expression was also discovered to be elevated in prostate cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer.
Abstract translation: 本申请提供了新型人基因MICAL2-PV，其表达在前列腺癌中显着升高。 此外，它提供由该基因编码的多肽以及由PCOTH编码的多肽，其表达也被发现在前列腺癌中升高。 由该基因编码的基因和多肽可以用于例如前列腺癌的诊断中，作为用于开发针对该疾病的药物的靶分子，以及用于减轻前列腺癌的细胞生长。
-
公开(公告)号：BRPI0815757A2
公开(公告)日：2015-02-18
申请号：BRPI0815757
申请日：2008-08-20
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
Abstract: The invention features methods for detecting prostate cancer, especially hormone-refractory prostate cancer (HRPC) or castration-resistant prostate cancer (CRPC), by detecting over-expression of PKIB or NAALADL2 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing prostate cancer including HRPC, based on the over-expression of PKIB or NAALADL2 in the prostate cancer, the cell proliferation function of PKIB or NAALADL2, the intracellular localization of PKIB or NAALADL2 or the interaction between PKIB and PKA-C. Also, provided are a method for treating prostate cancer by administering a double-stranded molecule against the PKIB or NAALADL2 gene. The invention also provides products, including the double-stranded molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods.
-
公开(公告)号：DE602006020451D1
公开(公告)日：2011-04-14
申请号：DE602006020451
申请日：2006-07-19
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
IPC: G01N33/574 , C12Q1/48
-
公开(公告)号：AT500511T
公开(公告)日：2011-03-15
申请号：AT06781626
申请日：2006-07-19
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
IPC: G01N33/574 , C12Q1/48
-
公开(公告)号：CA2697512A1
公开(公告)日：2009-03-05
申请号：CA2697512
申请日：2008-08-20
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
Abstract: The invention features methods for detecting prostate cancer, especially hormone-refractory prostate cancer (HRPC) or castration-resistant prostate cancer (CRPC), by detecting over-expresion of PKIB or NAALADL2 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing prostate cancer including HRPC, based on the over-expression of PKIB or NAALADL2 in the prostate cancer, the cell proliferation function of PKIB or NAALADL2, the intracellular localization of PKIB or NAALADL2 or the interaction between PKIB and PKA-C. Also, provided are a method for treating prostate cancer by administering a double-stranded molecule against the PKIB or NAALADL2 gene. The invention also provides products, including the double-stranded molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods.
-
Patent Agency Ranking
公开(公告)号：CA2500861A1
公开(公告)日：2004-04-15
申请号：CA2500861
申请日：2003-09-22
Applicant: ONCOTHERAPY SCIENCE INC , UNIV TOKYO
Inventor： NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI , KATAGIRI TOYOMASA , NAKAMURA YUSUKE
Abstract: Objective methods for detecting and diagnosing prostate cancer (PRC) or prostatic intraepithelial neoplasia (PIN) are described herein. In one embodiment, the diagnostic method involves the determining a expression leve l of PRC -associated gene that discriminate between PRC or PIN and nomal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment of either or both of PRC and PIN, methods of treating either or both of PRC and PIN and method of vaccinating a subject against either or both of PRC and PIN.
-
公开(公告)号：BRPI0715763A2
公开(公告)日：2013-09-24
申请号：BRPI0715763
申请日：2007-08-08
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
IPC: A61K31/7088 , A61K38/00 , A61K39/395 , A61P35/00 , C07K14/475 , C07K16/32 , C12N15/113 , C12Q1/68 , G01N33/53
-
公开(公告)号：BRPI0708409A2
公开(公告)日：2011-05-31
申请号：BRPI0708409
申请日：2007-02-28
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
IPC: G01N33/574 , C07K16/30
Abstract: REG4, a new member of REG family was identified as a biomarker of pancreatic adenocarcinoma. The present invention provides sandwich ELISA to detect serum REG4 in patients with resectable pancreatic cancers i.e. PDACs. The present invention also provides a method for diagnosing a pancreatic cancer using REG4 as a serological marker.
-
公开(公告)号：CA2660516A1
公开(公告)日：2008-02-21
申请号：CA2660516
申请日：2007-08-08
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAGAWA HIDEWAKI , NAKAMURA YUSUKE , NAKATSURU SHUICHI
IPC: A61K31/7088 , A61K38/00 , A61K39/395 , A61P35/00 , C07K14/475 , C07K16/32 , C12N15/113 , C12Q1/68 , G01N33/53
Abstract: The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of an siRNA that inhibits expression of REG4 or KIAA0101. Methods of treating cancer are also within the inventi on. The invention also features products, including nucleic acid sequences a nd vectors as well as to compositions comprising them, useful in the provide d methods. The invention also provides a method for inhibiting of tumor cell , for example pancreatic cancer cell, prostatic cancer cell, breast cancer c ell, and bladder cancer cell, particularly pancreatic ductal adenocarcinoma (PDAC) by inhibiting REG4 gene. The present invention also relates to method s of treating or preventing PDAC in a subject comprising the step of adminis tering to said subject a pharmaceutically effective amount of an antibody or fragment thereof that binds to a protein encoded by REG4. The present inven tion also relates to methods of diagnosing chemo-radiation therapeutic resis tance of a cancer. The present invention also provides therapeutic agents or methods for treating cancer using the polypeptides. The polypeptides of the present invention are composed of an amino acid sequence which comprises po lypeptide which comprises QKGIGEFF/SEQ ID NO: 21. The polypeptides of the pr esent invention can be introduced into cancer cells by modifying the polypep tides with transfection agents such as poly-arginine.
-
公开(公告)号：AU2003264881A8
公开(公告)日：2004-04-23
申请号：AU2003264881
申请日：2003-09-22
Applicant: UNIV TOKYO , JAPAN PRESIDENT UNIV TOKYO , ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
Abstract: The present application provides novel human gene MICAL2-PV whose expression is markedly elevated in prostate cancers. Furthermore, it provides polypeptides encoded by the gene as well as polypeptides encoded by PCOTH which expression was also discovered to be elevated in prostate cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer.
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.022 seconds)
